These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30287230)

  • 1. Impact of sertraline on weight, waist circumference and glycemic control: A prospective clinical trial on depressive diabetic type 2 patients.
    Rachdi C; Damak R; Fekih Romdhane F; Ouertani H; Cheour M
    Prim Care Diabetes; 2019 Feb; 13(1):57-62. PubMed ID: 30287230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study.
    Derijks HJ; Janknegt R; Heerdink ER; De Koning FH; Krekels MM; Looij BJ; Egberts AC
    J Clin Psychopharmacol; 2009 Aug; 29(4):405-8. PubMed ID: 19593191
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycemic control improvement through treatment of depression using antidepressant drugs in patients with diabetes mellitus type 1.
    Komorousova J; Beran J; Rusavy Z; Jankovec Z
    Neuro Endocrinol Lett; 2010; 31(6):801-6. PubMed ID: 21196929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial.
    Lustman PJ; Clouse RE; Nix BD; Freedland KE; Rubin EH; McGill JB; Williams MM; Gelenberg AJ; Ciechanowski PS; Hirsch IB
    Arch Gen Psychiatry; 2006 May; 63(5):521-9. PubMed ID: 16651509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH.
    Mandosi E; Fallarino M; Rossetti M; Gatti A; Morano S
    Diabetes Res Clin Pract; 2009 May; 84(2):e18-20. PubMed ID: 19297054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes with comorbid depression: role of SSRI in better glycemic control.
    Gehlawat P; Gupta R; Rajput R; Gahlan D; Gehlawat VK
    Asian J Psychiatr; 2013 Oct; 6(5):364-8. PubMed ID: 24011681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study: A Randomized Controlled Multicenter Trial.
    Petrak F; Herpertz S; Albus C; Hermanns N; Hiemke C; Hiller W; Kronfeld K; Kruse J; Kulzer B; Ruckes C; Zahn D; Müller MJ
    Diabetes Care; 2015 May; 38(5):767-75. PubMed ID: 25690005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controlled diabetes mellitus.
    Petrak F; Herpertz S; Albus C; Hermanns N; Hiemke C; Hiller W; Kronfeld K; Kruse J; Kulzer B; Ruckes C; Müller MJ
    BMC Psychiatry; 2013 Aug; 13():206. PubMed ID: 23915015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sertraline in patients with newly diagnosed depression and type 2 diabetes mellitus or hypertension: An observational study from south India.
    Padmapriya C; Pushkarapriya S; Shanmugapriya N; Sushmitha KP; Karthik S; Rajanandh MG
    Diabetes Metab Syndr; 2020; 14(5):1065-1068. PubMed ID: 32645649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depression treatment and its impact upon the quality of life in patients with diabetes type 2 - the Croatian study.
    Filipcić I; Margetić B; Simunović I; Jakovljević M
    Psychiatr Danub; 2010 Jun; 22(2):231-5. PubMed ID: 20562752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
    Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
    Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity.
    Li CJ; Li J; Zhang QM; Lv L; Chen R; Lv CF; Yu P; Yu DM
    Cardiovasc Diabetol; 2012 Nov; 11():142. PubMed ID: 23153177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
    Fava M; Wisniewski SR; Thase ME; Baker RA; Tran QV; Pikalov A; Yang H; Marcus RN; Berman RM
    J Clin Psychopharmacol; 2009 Aug; 29(4):362-7. PubMed ID: 19593176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice?
    Moreno-Fernandez J; Garcia-Seco JA; Seco Segura AM; Garcia-Seco F; Rozas Moreno PJ; Aguirre Sanchez-Covisa M
    Prim Care Diabetes; 2020 Feb; 14(1):68-74. PubMed ID: 31171461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.